Status:
COMPLETED
A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Herpes Zoster
Eligibility:
All Genders
50-59 years
Phase:
PHASE1
Brief Summary
The purpose of this study was to assess the safety and tolerability of gamma-irradiated varicella-zoster virus (VZV) vaccine A (Part 1) and gamma-irradiated VZV vaccine B and C (Part 2) and to determi...
Eligibility Criteria
Inclusion
- Must be 50 to 59 years of age
- No fever on vaccination days
- Must have had chickenpox or lived in an area where the chickenpox virus is prevalent for 30 or more years
- Females of child-bearing potential must use acceptable forms of birth control
Exclusion
- Prior history of shingles
- Prior receipt of any chickenpox or shingles vaccine
- Pregnant or breastfeeding
- Received or expect to receive a live virus vaccine (such as measles, mumps, rubella) from 4 weeks before the first visit through the last visit
- Received or expect to receive an inactivated vaccine (such as tetanus or pneumonia) from 7 days before the first visit through the last visit
- Received immunoglobulin or blood products
- Receiving treatment that may weaken the immune system
- Have an immune system disorder
Key Trial Info
Start Date :
December 12 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 16 2009
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT00696709
Start Date
December 12 2008
End Date
November 16 2009
Last Update
November 8 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.